Argus Research Maintains Buy on Eli Lilly, Raises Price Target to $620
Portfolio Pulse from Benzinga Newsdesk
Argus Research analyst David Toung maintains a 'Buy' rating on Eli Lilly (LLY) and raises the price target from $470 to $620.
September 05, 2023 | 3:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Argus Research has maintained a 'Buy' rating on Eli Lilly and increased the price target from $470 to $620.
The raised price target by Argus Research indicates a positive outlook for Eli Lilly. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100